Key contacts

Will Corkill

Will Corkill

Simon Wilson

Simon Wilson

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
NSW 2000
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Sealegs Corporation Kreuz Holdings
See more

Latest research

Pacific Edge

On the road to full US commercialisation

Outlook | Pharmaceutical & Healthcare | 26/06/2016

Pacific Edge has made solid progress in recent months toward the start of broad commercialisation of its bladder cancer diagnostics tests in the US, with a third test becoming available there in mid-2016. In February, the Veterans Administration (VA) handed down a positive decision on its Cxbladder testing technology just as large-scale User Programmes in the US near completion. The Kaiser Permanente (KP) pilot is expected to be completed by the end of 2016 and could result in significant sales traction.

Mineral Commodities

Rising production profile, exploration appeal

Update | Mining | 24/06/2016

Mineral Commodities (MRC) plans to complete its Tormin plant optimisation in July 2016. It is expected to increase heavy mineral (HM) recoveries and produce higher-grade, higher value-add products and result in additional production capacity and enhanced operating flexibility. MRC will be able to capitalise on its expanded exploration programme for high-grade resources in the region.

YPB Group

Upgrading on guidance

Update | Industrial Support Services | 10/06/2016

YPB Group (YPB) combines patented anti-counterfeiting technology with security packaging solutions, consulting and forensic services to help businesses protect their brands from the risks of counterfeiting and product diversion. The company recently completed a A$4.54m share placement and provided guidance to the market for FY17 profit before tax of A$5m. We have incorporated this guidance and the effect of the share placement into our forecasts, resulting in a 24% upgrade to our FY17e PBT to A$5.4m.…


Three Cavatak/checkpoint combination trials

Update | Pharmaceutical & Healthcare | 10/06/2016

Additional data presented at ASCO confirm the potential for synergistic combinations of Cavatak with immune checkpoint inhibitor (ICI) drugs to improve the proportion of cancer patients who respond to ICI therapy. Three Phase Ib trials are underway testing Cavatak in combination with Yervoy or Keytruda in melanoma, lung and bladder cancers. Initial data in April showed an impressive 67% response rate in the first six patients in the MITCI study of Cavatak and Yervoy in melanoma. Further updates on…

High Peak Royalties

Termination of coverage

Termination | Oil & Gas | 02/06/2016

Edison Investment Research is terminating coverage on High Peak Royalties (HPR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.


Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports